- Company
- Bayer releases 2 new CVD drugs with reimb in KOR
- by Eo, Yun-Ho Mar 4, 2024 05:52am
- Bayer Korea, which has been slow to launch new drugs, is making a comeback, recently succeeding in reimbursing two of its cardiovascular drugs in Korea. According to industry sources, Bayer Korea launched its heart failure drug ‘Verquvo (vericiguat)’ with reimbursement on September 1 last year and its kidney disease drug ‘Kerendia (finere
- Policy
- Will the novel anticancer drug Enhertu be reimb in April?
- by Lee, Tak-Sun Mar 4, 2024 05:52am
- After going through two Cancer Disease Deliberation Committee meetings and two Drug Reimbursement Evaluation Committee meetings, the anticancer drug ‘Enhertu’ has finally started drug pricing negotiations with the National Health Insurance Service. As the drug has passed drug evaluations after repeated revisions, the negotiations are ex
- Company
- Hanmi Pharm ‘confirms the effect of SERM+Vitamin D combo’
- by Son, Hyung-Min Feb 29, 2024 06:03am
- Hanmi Pharmaceutical announced on the 27th that the results of big data-based research on 'SERM+Vitamin D combination drugs', including its own ‘RaboneD’, were published in the SCI-level international journal, 'Osteoporosis International'. RaboneD is an osteoporosis treatment developed by Hanmi Pharmaceutical that combines vitamin D
- Product
- NA Opp party in unison say ‘it's time for INN prescribing'
- by Kim JiEun Feb 29, 2024 06:03am
- Opposition lawmakers unanimously voiced the need to introduce International Nonproprietary Names (INN) prescribing and the resolution of the unstable drug supply and demand. The National Assembly representatives who attended the 70th Regular General Assembly of the Korean Pharmaceutical Association Delegates that was held at The K Hotel in Se
- Company
- Roche Korea appoints Ezat Azem as new CEO
- by Eo, Yun-Ho Feb 29, 2024 06:03am
- Roche Korea is welcoming its new CEO, who will take up the position after a two-month vacancy. According to an interview, Roche Korea recently appointed Ezat Azem as new CEO. Before his appointment in Korea, Ezat Azem was a General Manager in Roche’s Greece subsidiary. Ezat Azem joined Roche’s Israel subsidiary in 1997 and worked
- Company
- K-Bio’s potential rises in targeted anticancer therapy
- by Son, Hyung-Min Feb 29, 2024 06:03am
- The achievements made by the pharmaceutical and bio-industry companies in Korea in developing targeted antitumor therapies are being introduced at academic conferences overseas. iLeadBMS and PharosiBio have announced positive preclinical study results, and have received the green light to enter main clinical trials. The ESMO Targeted Anticanc
- Company
- Saxenda and Qsymia take up 57% of the obesity market share
- by Chon, Seung-Hyun Feb 28, 2024 10:35am
- Last year, Korea’s obesity drug market size reached its largest size in history. It broke the record in 2019, and since then, the market size expanded for five consecutive years. Saxenda and Qsymia account for 60 % of the total market share. Meanwhile, sales of previous obesity drugs, such as psychotropic drugs, are declining, further polarizin
- Company
- KRPIA appoints Sanofi CEO Kay Bae as new chair
- by Feb 28, 2024 05:50am
- The Korean Research-based Pharmaceutical Industry Association (KRPIA) announced on the 23rd that it has appointed Kay Bae (Bae Kyung-eun), Country Lead of Sanofi-Aventis Korea, as the 15th chair of KRPIA. Bae served on the KRPIA board of directors in September 2013, and she has been a member of the vice-chair body, contributing to the g
- Policy
- Patients bear 100% of Imfinzi cost for biliary tract cancer
- by Lee, Tak-Sun Feb 28, 2024 05:50am
- Reimbursement standards have been prepared for the use of combination therapy in biliary tract cancer in Korea. However, in consideration of health insurance finances, patients are required to the full cost of the high-priced immuno-oncology drugs. The Health Insurance Review and Assessment Service recently added the combination of immun
- Company
- Immuno-oncology market triples in 4 years
- by Son, Hyung-Min Feb 28, 2024 05:50am
- Sales in the immuno-oncology market surpassed KRW 700 billion last year, driven by the surge in sales of Keytruda and Opdivo. The market has more than tripled in size over the past 4 years. Keytruda and Opdivo together accounted for 72.4% of the market and generated more than KRW 500 billion in sales. The market’s prospects are also bright with
